Tissue Plasminogen Activator Therapy is Estimated to Witness High Growth Owing to Opportunity in Neurovascular Conditions Management

 

Acute Ischemic Stroke (AIS) Market

Acute ischemic stroke (AIS) occurs due to inadequate blood flow or a blockage in an artery supplying blood to the brain. This leads to reduction in oxygen and nutrients to brain cells causing cell death or damage. Common symptoms of stroke include sudden numbness or weakness, especially on one side of the body, sudden confusion, trouble speaking or understanding speech, sudden trouble seeing in one or both eyes, sudden trouble walking, dizziness, loss of balance or coordination and sudden severe headache with no known cause. There are various treatment options available for AIS including thrombolytic therapy, mechanical thrombectomy, medications etc. Thrombectomy is a minimally invasive procedure to surgically remove blood clots from arteries in the brain to restore blood flow. Increased adoption of mechanical thrombectomy procedures over thrombolytic therapies owing to improved outcomes is propelling the growth of the AIS market.

 
The global Acute Ischemic Stroke (AIS) Market is estimated to be valued at US$ 12 Bn in 2023 and is expected to exhibit a CAGR of 18% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
 
Market Dynamics:
One of the key drivers for the growth of the acute ischemic stroke market is the increased adoption of thrombectomy procedures. Thrombectomy is minimally invasive surgery to remove blood clots from arteries of the brain to restore blood flow. It has better outcomes compared to standard intravenous thrombolysis with clot-busting drugs alone. The procedures have shown reduced disability and improved functional outcomes in patients when combined with standard medical therapies. Hence more hospitals are adopting thrombectomy as a standard of care and first-line treatment for AIS patients within 24 hours of symptoms, which is propelling market growth.
 
SWOT Analysis
 
Strength: Acute ischemic stroke market has several ongoing clinical trials that will demonstrate strong efficacy for treatments. Researchers are conducting large, long term clinical studies to evaluate new drugs for effectiveness and safety. Telestroke programs allow specialists to assess patients in rural areas via video conferencing, expanding access to care.
 
Weakness: High costs associated with stroke treatments and rehabilitation therapy make them inaccessible for many patients. Lack of awareness among people about early symptoms of stroke and importance of rapid medical intervention lead to poor health outcomes.
 
Opportunity: Growing geriatric population vulnerable to strokes creates a large patient population for treatments. Development of novel drugs that can safely dissolve blood clots or restore blood flow will address unmet needs. Wearable devices and mobile healthcare apps provide opportunities for remote monitoring of high-risk patients.
 
Threats: Stringent regulations for drug approvals delay market access for novel therapies. Patents expiring on blockbuster drugs increase competition from generics. Medical device market facing price pressure due to healthcare reforms to reduce costs.
 
Key Takeaways
 
The Global Acute Ischemic Stroke (AIS) Market Size is expected to witness high growth over the forecast period of 2023 to 2030 supported by aging demographics, technological advancements, and strong pipeline of emerging therapies. The market currently lacks effective treatment options, indicating strong potential for novel drug candidates. The global Acute Ischemic Stroke (AIS) Market is estimated to be valued at US$ 12 Bn in 2023 and is expected to exhibit a CAGR of 18% over the forecast period 2023 to 2030.
 
Regional analysis indicates North America dominates due to large healthcare budgets and widespread adoption of telestroke programs and revascularization procedures. However, Asia Pacific is emerging as the fastest growing market for AIS treatments driven by increasing incomes, lifestyles changes, and expansion of private healthcare insurance.
 
Key players operating in the acute ischemic stroke market are Genentech, Boehringer Ingelheim, Daiichi Sankyo, Biogen, and AstraZeneca. These companies have strong portfolio of drugs in late stage clinical trials evaluating benefits for extending treatment time windows and improving outcomes in vulnerable patient groups.

Get More Insights Here
https://www.newswirestats.com/acute-ischemic-stroke-ais-market-size-share-growth-outlook-2023/
​

Comments

Post a Comment

Popular posts from this blog

"Global Heparin Market: Current Trends and Future Prospects"

Image
  Heparin, a crucial anticoagulant, has been a mainstay in the pharmaceutical industry for many years. It plays a pivotal role in preventing and treating conditions such as deep vein thrombosis, pulmonary embolism, and various cardiovascular diseases. As we delve into the current state of the heparin market, we will explore the trends, challenges, and opportunities that shape this vital segment of the pharmaceutical industry. Market Overview: The global heparin market has experienced steady growth over the years, driven by an aging population, increasing cases of cardiovascular diseases, and a rising awareness of the importance of anticoagulants in healthcare. Heparin is available in various forms, including unfractionated heparin (UFH) and low molecular weight heparin (LMWH), each with its own set of applications and market dynamics. Trends: 1.      Rising Demand for LMWH : Low molecular weight heparin is gaining popularity due to its ease of administr...
Read more

"Advancements in Cystic Fibrosis Treatment: A Comprehensive Market Analysis"

Image
  The cystic fibrosis market has seen significant advancements and changes in recent years. Cystic fibrosis is a genetic disorder that affects the lungs and digestive system, leading to thick and sticky mucus production that can cause serious respiratory and digestive complications. The introduction of new therapies and treatments, such as CFTR modulators, has revolutionized the management of cystic fibrosis, offering hope and improved quality of life for patients. These drugs target the underlying genetic mutations responsible for the condition, helping to alleviate symptoms and slow disease progression. However, challenges remain in the cystic fibrosis market . Access to these ground-breaking therapies can be limited due to high costs, and ongoing research is needed to develop treatments for all genetic mutations associated with the disease. Additionally, the market continues to evolve as new therapies and innovations emerge. Collaborative efforts between pharmaceutical compani...
Read more

"Advancements in Thyroid Cancer Drugs Market: A Comprehensive Analysis"

Image
  Thyroid cancer is a relatively rare but potentially life-threatening condition that affects the thyroid gland. It has been on the radar of medical researchers and pharmaceutical companies for quite some time, leading to significant advancements in the development of thyroid cancer drugs. In this blog, we will explore the latest developments in the thyroid cancer drugs market and how they are shaping the landscape of treatment options for thyroid cancer patients. 1.      Targeted Therapies: One of the most notable advancements in thyroid cancer treatment is the emergence of targeted therapies. These drugs are designed to specifically target cancer cells, sparing healthy cells and reducing side effects. Some targeted therapies approved for thyroid cancer include Sorafenib and Lenvatinib, which have shown promise in slowing down tumor growth and improving patient outcomes. 2.      Immunotherapy: Immunotherapy has gained significant at...
Read more